Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer.

Chintamani, Gogne A, Khandelwal R, Tandon M, Jain S, Kumar Y, Narayan N, Bamal R, Srinivas S, Saxena S.

JRSM Short Rep. 2011 Mar 14;2(3):15. doi: 10.1258/shorts.2010.010072.

2.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
3.

Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer.

Walker LG, Heys SD, Walker MB, Ogston K, Miller ID, Hutcheon AW, Sarkar TK, Ah-See AK, Eremin O.

Eur J Cancer. 1999 Dec;35(13):1783-8.

PMID:
10673992
4.

Patient and provider delays in breast cancer patients attending a tertiary care centre: a prospective study.

Chintamani, Tuteja A, Khandelwal R, Tandon M, Bamal R, Jain S, Narayan N, Srinivas S, Kumar Y.

JRSM Short Rep. 2011 Oct;2(10):76. doi: 10.1258/shorts.2011.011006. Epub 2011 Oct 10.

5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
7.

Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.

Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F.

Oncology. 2010;79(3-4):255-61. doi: 10.1159/000322189. Epub 2011 Mar 4.

PMID:
21372600
8.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.

Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.

PMID:
20113825
9.

Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm.

Bergerot CD, Clark KL, Nonino A, Waliany S, Buso MM, Loscalzo M.

Palliat Support Care. 2015 Apr;13(2):115-23. doi: 10.1017/S1478951513000849. Epub 2013 Nov 4.

PMID:
24182842
10.

Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.

Taira N, Iwata H, Hasegawa Y, Sakai T, Higaki K, Kihara K, Yamaguchi T, Ohsumi S, Shimozuma K, Ohashi Y.

Breast Cancer Res Treat. 2014 May;145(1):155-64. doi: 10.1007/s10549-014-2935-5. Epub 2014 Apr 2.

PMID:
24692082
11.

Levels of distress in breast cancer survivors approaching discharge from routine hospital follow-up.

Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N, Reed M.

Psychooncology. 2013 Aug;22(8):1866-71. doi: 10.1002/pon.3229. Epub 2012 Dec 2.

PMID:
23203833
12.

Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.

Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE.

Cancer. 1996 Jul 1;78(1):91-100.

PMID:
8646731
13.

FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study.

Kang JI, Chung HC, Jeung HC, Kim SJ, An SK, Namkoong K.

Psychoneuroendocrinology. 2012 Sep;37(9):1569-76. doi: 10.1016/j.psyneuen.2012.02.017. Epub 2012 Mar 28.

PMID:
22459275
14.

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.

Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, Skaltsa K, Domènech B, Lomeña F, Pons F.

Q J Nucl Med Mol Imaging. 2012 Jun;56(3):291-8.

PMID:
22695339
16.

Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.

Chintamani, Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P.

World J Surg Oncol. 2005 Sep 14;3:61.

17.

Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer.

Kuo HH, Chiu MJ, Liao WC, Hwang SL.

J Formos Med Assoc. 2006 Jan;105(1):64-9.

18.

Distress, anxiety, and depression in cancer patients undergoing chemotherapy.

Pandey M, Sarita GP, Devi N, Thomas BC, Hussain BM, Krishnan R.

World J Surg Oncol. 2006 Sep 26;4:68.

19.
20.

Neoadjuvant docetaxel in locally advanced breast cancer.

Hutcheon AW, Heys SD, Sarkar TK; Aberdeen Breast Group.

Breast Cancer Res Treat. 2003;79 Suppl 1:S19-24. Review.

PMID:
12868802

Supplemental Content

Support Center